CytomX Therapeutics, Inc. (CTMX) |
|
1.81 0.02 (1.12%)
|
11-25 13:00 |
|
Open: |
1.81 |
Pre. Close: |
1.79 |
|
High:
|
1.835 |
Low:
|
1.7875 |
|
Volume:
|
440,353 |
Market Cap:
|
120(M) |
|
|
|
Technical analysis |
as of: 2022-11-28 9:17:38 AM |
|
Overall:
|
  |
| Stoxline posted a BUY today, upgraded from lower rating. Upward movement to be expected. |
| Target: |
Six months: 2.26 One year: 2.64 |
| Support: |
Support1: 1.46 Support2: 1.16 |
| Resistance: |
Resistance1: 1.94 Resistance2: 2.26 |
| Pivot: |
1.45 |
| Moving Average: |
MA(5): 1.79 MA(20): 1.41
MA(100): 1.47 MA(250): 2.49  |
| MACD: |
MACD(12,26): 0.1 Signal(9): 0 |
| Stochastic oscillator: |
%K(14,3): 87.4 %D(3): 87.8 |
| RSI: |
RSI(14): 69 |
| 52-week: |
High: 6.96 Low: 1.16 |
| Average Vol(K): |
3-Month: 1,346 (K) 10-Days: 5,862 (K) |
|
Price, moving averages and Bollinger Bands |
|
Price has closed above its short-term moving average. Short-term moving average is currently above mid-term; and above long-term moving average. From the relationship between price and moving averages: This stock is BULLISH in short-term; and NEUTRAL in mid-long term.[ CTMX ] has closed below upper band by 15.5%. Bollinger Bands are 167.8% wider than normal. The large width of the bands suggest high volatility as compared to its normal range. The bands have been in this wide range for 4 days. This is a sign that the current trend might continue. |
|
|
Stock Price Prediction |
Update at 5:00pm EST |
|
If tomorrow:
|
Open lower
|
Open higher
|
|
High:
|
1.84 - 1.85 |
1.85 - 1.85 |
|
Low:
|
1.77 - 1.78 |
1.78 - 1.79 |
|
Close:
|
1.79 - 1.81 |
1.81 - 1.82 |
|
Company Description |
|
CytomX Therapeutics, Inc. operates as an oncology-focused biopharmaceutical company in the United States. The company develops antibody therapeutics based on its Probody technology platform for the treatment of cancer. The company's product candidates include CX-2009, an antibody drug conjugates (ADC) against CD166, which is in Phase II clinical trials for the treatment of breast cancer; CX-2029 that is in Phase II clinical trials for the treatment of squamous non-small cell lung cancer, head and neck squamous cell carcinoma, esophageal and gastro-esophageal junction cancers, and diffuse large B-cell lymphoma; BMS-986249, a CTLA-4 Probody therapeutic drug, which is in Phase I/II clinical trials for the treatment of metastatic melanoma; and BMS-986288, an anti-CTLA-4 Probody drug, which is in Phase I clinical trials for the treatment of solid tumors. It also develops CX-2043, a conditionally activated ADC targeting the epithelial cell adhesion molecule, as well as CX-904, a conditionally activated epidermal growth factor receptor for the treatment of solid tumor. The company has strategic collaborations with AbbVie Ireland Unlimited Company, Amgen, Inc., Bristol-Myers Squibb Company, ImmunoGen, Inc., Pfizer Inc., and Astellas Pharma Inc. to develop Probody therapeutics. CytomX Therapeutics, Inc. was founded in 2008 and is headquartered in South San Francisco, California. |
Headline News |
Wed, 23 Nov 2022
Biotech Stock Roundup: CTMX Surges on REGN's Deal, APLS Up on Regulatory Update - Nasdaq
Fri, 18 Nov 2022
CytomX (CTMX) Stock Surges on Oncology Deal With Regeneron - Zacks Investment Research
Thu, 17 Nov 2022
Healthcare Stocks Making Moves Thursday: CTMX, BDSX, TCRT, NRXP, NOTV, BVS, TNYA, IMCC - InvestorsObserver
Thu, 17 Nov 2022
Health Care Sector Update for 11/17/2022: CTMX,REGN,ARDX,TNYA,BNOX - Nasdaq
Thu, 10 Nov 2022
CytomX Therapeutics Inc (CTMX) is down 3.23% Thursday In Premarket Trading - InvestorsObserver
Thu, 10 Nov 2022
Growth Investors: Industry Analysts Just Upgraded Their CytomX Therapeutics, Inc. (NASDAQ:CTMX) Revenue Forecasts By 14% - Simply Wall St
|
Financial Analysis |
| Price to Book Value: |
Outperform |
| P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
| Price to Earnings: |
Underperform |
| PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
| Discounted cash flow: |
Outperform |
| DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
| Return on Assets: |
Underperform |
| ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
| Return on Equity: |
Underperform |
| ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
| Debt to Equity: |
Outperform |
| evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
|
|
|
|
|
|
| Free Technical Analysis Charts
|
|
|
Stock Basics & Statistics |
| Exchange: NASDAQ |
| Sector: Healthcare |
| Industry: Biotechnology |
| Shares Out. |
66 (M) |
| Shares Float |
55 (M) |
|
% Held by Insiders
|
1.2 (%) |
|
% Held by Institutions
|
58.3 (%) |
|
Shares Short
|
997 (K) |
|
Shares Short P.Month
|
1,200 (K) |
Stock Financials |
|
EPS
|
-1.41 |
|
EPS Est Next Qtl
|
-0.41 |
|
EPS Est This Year
|
-1.5 |
|
EPS Est Next Year
|
-1.41 |
|
Book Value (p.s.)
|
0.43 |
|
Profit Margin (%)
|
-135.7 |
|
Operating Margin (%)
|
-127.5 |
|
Return on Assets (ttm)
|
-19.2 |
|
Return on Equity (ttm)
|
-139.3 |
|
Qtrly Rev. Growth
|
-3.8 |
|
Gross Profit (p.s.)
|
1.05 |
|
Sales Per Share
|
1.08 |
|
EBITDA (p.s.)
|
-1.35 |
|
Qtrly Earnings Growth
|
0 |
|
Operating Cash Flow
|
-141 (M) |
|
Levered Free Cash Flow
|
-46 (M) |
Stock Valuations |
|
PE Ratio
|
-1.29 |
|
PEG Ratio
|
1.3 |
|
Price to Book value
|
4.2 |
|
Price to Sales
|
1.66 |
|
Price to Cash Flow
|
-0.86 |
Stock Dividends |
|
Dividend
|
0 |
|
Forward Dividend
|
0 |
|
Dividend Yield
|
0% |
|
Dividend Pay Date
|
Invalid DateTime. |
|
Ex-Dividend Date
|
Invalid DateTime. |
|
Your Ad Here
|
|
